头孢曲松钠(Ceftriaxone Sodium) - 药物靶点：PBPs_在研适应症：与感染相关的关节病，骨感染，术后感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Acantex、CTRX、Ceftezole Sodium

+ [25]

靶点

PBPs

作用方式

抑制剂

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂

治疗领域

感染神经系统疾病呼吸系统疾病+ [3]

在研适应症

与感染相关的关节病骨感染术后感染+ [18]

非在研适应症

回肠炎

原研机构

F. Hoffmann-La Roche Ltd.

在研机构

东北制药集团沈阳第一制药有限公司

Juno Pharmaceuticals Pty Ltd.

上海罗氏制药有限公司

+ [2]

非在研机构

Hoffmann-La Roche, Inc.

Theriva Biologics, Inc.

权益机构

Roche Holding AGHasten Biopharmaceutical Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1984-12-21),

细菌感染

最高研发阶段(中国)批准上市

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C18H18N8Na2O7S3

InChIKeyVUGBLGCUPUUDOI-BBJOQENWSA-N

CAS号74578-69-1

查看全部结构式(3)

关联

149

项与头孢曲松钠相关的临床试验

NCT03895567

/ Not yet recruiting临床1期IIT

A Randomised Crossover Study of the Pharmacokinetics, Safety and Tolerability of Two Rectal Formulations of Ceftriaxone Compared to Parenteral Ceftriaxone, in Healthy Thai Adults.

Phase 1, three-way cross-over, randomised, open label comparison of intravenous versus two rectal dosage forms of ceftriaxone in 37 healthy Thai adults.
The following regimens will be evaluated in random order in all participants:
A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1-hard-shell gelatin capsule (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2-rectodispersible mannitol-based tablet (1 x 500mg)
Possible schedules: ABC, ACB, BAC, BCA, CAB, CBA. Each recipient will receive a single treatment dose of each of the three formulations in an order predetermined by a computer generated randomisation list. This will be a constrained randomization which ensures approximately balanced proportions for all six schedules (either 6 or 7 participants per schedule). There will be 7-28 days washout period between doses. The last follow up visit is 28 (+ 2) days after final dose. Participants lost to follow-up or unevaluable for any reason before completion of pharmacokinetic sampling after the final dose will be replaced at the discretion of the investigators with another participant of the same population, if either sample size or completeness of dataset is compromised.
This study is funded by the Medical Research Council. The grant reference number is MR/W021560/1

开始日期2025-09-01

申办/合作机构

University of Oxford

NCT06828952

/ Not yet recruitingN/AIIT

Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis

From this study, it can be concluded that patients who meet the following criteria are more likely to fail expectant management and thus should not be considered for the NOM of uncomplicated acute appendicitis. These include the duration of symptoms before presenting to a surgical emergency , the presence of fever within 24 hours of presenting to a surgical emergency, TLC cells/dL, CRP mg/L, appendix diameter mm, modified Alvarado score , and adult appendicitis score .

开始日期2025-06-22

申办/合作机构

Assiut University

[+1]

NCT06785402

/ Not yet recruiting临床1/2期IIT

Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Trial of Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease

Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS). The goal of this study is to investigate if giving Ceftriaxone every 5 days for about 6 weeks kills the organism that produces persistent Lyme infection.
Enrolled participants will be randomized 1:1 receiving either pulse-dosed ceftriaxone or placebo [dextrose (5% in water), (D5W)], intravenously. Participants will be evaluated at each of the study visits, and then in a follow-up phase out to 12 months. They will be unblinded at 6 months and those randomized to the placebo group will be offered pulse-dosed ceftriaxone on the same schedule as those randomized to the drug group. All patients will be followed up for a total of 12 months post treatment initiation.

开始日期2025-05-15

申办/合作机构

Hackensack Meridian Health, Inc.

100 项与头孢曲松钠相关的临床结果

登录后查看更多信息

100 项与头孢曲松钠相关的转化医学

登录后查看更多信息

100 项与头孢曲松钠相关的专利（医药）

登录后查看更多信息

38,645

项与头孢曲松钠相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Pharmacist-led antibiotic interventions in infectious disease patients: a Pakistani tertiary care antimicrobial stewardship study

Article

作者: Ur Rehman, Naeem ; Maqbool, Sumeira ; Arif, Mehreen ; Hassan, Ali

BackgroundAntibiotics are widely used medications among infectious disease patients; therefore, proper monitoring and assessment are critical for ensuring rational use. Antimicrobial stewardship addresses the rational and appropriate use of antibiotics, which reinforces overall health outcomes. Ongoing antimicrobial resistance scenarios are an alarming condition for healthcare, necessitating continued practice of such assessments.ObjectivesTo evaluate the use of antibiotics in patients with infectious diseases, implement and evaluate clinical pharmacy interventions that adhere to antimicrobial stewardship protocols.MethodsA before and after study was designed to evaluate clinical pharmacy and antimicrobial stewardship interventions for infectious disease patients at a tertiary care hospital in Lahore. A Performa was designed for manual data collection. Study first identified the signal of error, implemented intervention and noted post-interventional followups.Results102 infectious disease cases were analyzed in total and proposed 136 interventions. Physicians accepted 66% of the interventions (90) and rejected the remaining ones as unjustified. The most accepted intervention was the spectrum-based choice (n = 30), followed by de-escalation of dose (n = 17). Use of ceftriaxone was very high (54 Pt.), followed by vancomycin (30 Pt.).ConclusionAntimicrobial stewardship programmes are critical for any institution's proper health care system. It ensures proper antibiotic outflow to patients, thereby improving their health status. The role of pharmacists in establishing an AMS in a hospital setting is a highly commendable activity that enhances healthcare collaboration and outcomes. Clinical pharmacists should implement such activities to improve patient care.

2025-12-31·Emerging Microbes & Infections

Emerging epidemic of the Africa-type plasmid in penicillinase-producing Neisseria gonorrhoeae in Guangdong, China, 2013–2022

Article

作者: Zheng, He-Ping ; Cheng, Kui ; Wu, Xing-Zhong ; Huang, Jin-Mei ; Tang, San-Mei ; Zhang, Zi-Yan ; Qin, Xiao-Lin ; Chen, Wen-Tao ; Chen, Yang ; Xue, Yao-Hua ; Zhou, Han ; Zhan, Qing-Xian ; Lan, Yin-Yuan ; Feng, Zhan-Qin

The prevalence of penicillinase-producing Neisseria gonorrhoeae (PPNG) is a crucial public health concern because of its resistance to penicillin and cephalosporins. From 2013 to 2022, a total of 1748 N. gonorrhoeae isolates from Guangdong, China, were examined for their antibiotic susceptibility and molecular epidemiological characteristics. PPNG prevalence increased markedly from 37.25% to 63.87%. This increase was accompanied by a shift in predominant plasmid types carried by PPNG isolates: the rate of PPNG isolates carrying the Africa-type plasmid increased from 18.42% to 91.55%, whereas the rate of isolates carrying the Asia-type plasmid decreased from 81.58% to 7.58%. The prevalence of bla_TEM-135, which is linked to cephalosporin resistance, declined from 52.63% to 4.37%, whereas that of bla_TEM-1 increased from 47.37% to 86.88%, and new bla_TEM variants emerged (10.99% by 2022). Most bla_TEM-1 (88.26%) and new bla_TEM alleles (83.70%) were associated with the Africa-type plasmid, whereas 86.79% of bla_TEM-135 alleles were linked to the Asia-type plasmid. Resistance to ceftriaxone was higher in the Asia-type group (11.67%) than in the Africa-type, Toronto/Rio-type and non-PPNG groups. Genotyping identified diverse sequence types (STs) among PPNGs, in which MLST ST7363, NG-STAR ST2477, NG-MAST ST17748, and NG STAR CC1124 were predominant. This study underscores the rising prevalence of PPNG in Guangdong driven by clonal expansion and changing plasmid dynamics, affecting cephalosporin resistance and highlighting the need for continued surveillance and research into effective treatment strategies.

2025-12-31·Gut Microbes

A modelling framework to characterize the impact of antibiotics on the gut microbiota diversity

Article

作者: Guedj, Jeremie ; Burdet, Charles ; Corbel, Tanguy ; Ferreira, Stéphanie ; de Gunzburg, Jean ; Olivares, Carlos ; Ruppé, Etienne ; Andremont, Antoine

Metagenomic sequencing deepened our knowledge about the role of the intestinal microbiota in human health, and several studies with various methodologies explored its dynamics during antibiotic treatments. We compared the impact of four widely used antibiotics on the gut bacterial diversity. We used plasma and fecal samples collected during and after treatment from healthy volunteers assigned to a 5-day treatment either by ceftriaxone (1 g every 24 h through IV route), ceftazidime/avibactam (2 g/500 mg every 8 h through IV route), piperacillin/tazobactam (1 g/500 mg every 8 h through IV route) or moxifloxacin (400 mg every 24 h through oral route). Antibiotic concentrations were measured in plasma and feces, and bacterial diversity was assessed by the Shannon index from 16S rRNA gene profiling. The relationship between the evolutions of antibiotic fecal exposure and bacterial diversity was modeled using non-linear mixed effects models. We compared the impact of antibiotics on gut microbiota diversity by simulation, using various reconstructed pharmacodynamic indices. Piperacillin/tazobactam was characterized by the highest impact in terms of intensity of perturbation (maximal [IQR] loss of diversity of 27.3% [1.9; 40.0]), while moxifloxacin had the longest duration of perturbation, with a time to return to 95% of baseline value after the last administration of 13.2 d [8.3; 19.1]. Overall, moxifloxacin exhibited the highest global impact, followed by piperacillin/tazobactam, ceftazidime/avibactam and ceftriaxone. Their AUC between day 0 and day 42 of the change of diversity indices from day 0 were, respectively, -13.2 Shannon unit.day [-20.4; -7.9], -10.9 Shannon unit.day [-20.4; -0.6] and -10.1 Shannon unit.day [-18.3; -4.6]. We conclude that antibiotics alter the intestinal diversity to varying degrees, both within and between antibiotics families. Such studies are needed to help antibiotic stewardship in using the antibiotics with the lowest impact on the intestinal microbiota.

275

项与头孢曲松钠相关的新闻（医药）

2025-04-01

·健识局

又有原研药退出！过气老药如何原地变身“印钞机”

3月28日，康桥资本以7.25亿元首付款，买下了卫材制药的雷贝拉唑钠肠溶片的中国权益。原研药这两年受到集采压力越来越大，医保部门新的挂网规则要求即使没进集采，药品定价也不能太高，要和集采药保持一定的价格关系。这把不少习惯卖高价的外企产品晾了起来，不少企业选择让这些品种退出市场。有人退场就有人进场。在医疗投资红海中，忙着抢创新药项目、赌赛道是常态。但康桥资本却另辟蹊径，专攻跨国药企不要的老药。这些药大部分专利早就过期，来未增长空间相当有限。康桥资本专挑老药买，打的什么算盘？类似家长群抱怨买不到进口阿奇霉素的季节，就是康桥资本实实在在尝到甜头的时候。2024年，康桥资本曾经买下的几款“过气”原研药顺利退出，旗下瑞松基金两年多时间收益达10亿元，内部收益率更是达到50%，保证了参与其中的国资保值增值。这可能正是康桥资本默默收购过气原研药的真正意图。康桥资本再收购一款老药雷贝拉唑钠是第二代质子泵抑制剂，由日本卫材和强生合作研发，主要用于胃溃疡、十二指肠溃疡等胃病。这款药早在1997就已在日本上市，2002年进入中国，几十年来销售一直很稳定。据药融云数据库显示，2022年雷贝拉唑钠肠溶片全国医院端销售额超13亿元，其中卫材以近40%的市场份额排名第一。但在2022年7月，豪森药业的雷贝拉唑钠肠溶片成为国内首家通过一致性评价的产品。此后，济川药业、安必生制药、石药集团等众多药企的雷贝拉唑钠肠溶片陆续获批。在国产仿制药的冲击下，卫材药业市场份额不断下降。随着入局玩家的增多，雷贝拉唑钠也没能逃离集采的命运。在第九批集采中，卫材的雷贝拉唑钠肠溶片报价超过最高限价10倍，等同于弃标。2024年4月，由于价格高于“上海红线价”，卫材雷贝拉唑钠肠溶片更是直接被河北省撤网。其市场份额随之不断下降，看上去这个产品生命周期已经步入尾声，卫材卖掉它也就不意外。对于这样一款卫材不要的老药，康桥资本花费7.25亿元首付款买下来以后，要怎么盘活它？对此，康桥资本已经有过成功经验。康桥资本成立于2014年，曾经与大部分传统的私募股权基金并无二致，从事着少数股权投资。但近些年，资本涌入创新药赛场，生物医药企业的估值水涨船高，好的明星企业投资都相当拥挤。与其内卷，不如另辟蹊径创造价值，近两年跨国药企纷纷转让原研老药的销售权，正好给了康桥资本这样一个机会。海森生物就是康桥资本联合地方政府操刀的第一个跨国药企资产剥离项目，康桥资本在2年时间里收回所有投资。在首战告捷后，康桥资本可能是认为也在尝试将“投资者-运营商”的方法论继续复制。这次收购雷贝拉唑，康桥资本“二次开发”过气专利药，俨然成了商业模式，那么它到底是怎么做到的呢？如何让老药变废为宝？2022年，康桥资本刚拉来合肥产投集团、合肥肥东县，通过瑞松基金共同投资组建海森生物。2022年3月，这家药企新秀打响了第一枪，以2.3亿美元收购了武田制药心血管及代谢领域的五款产品。当时这个项目不少基金都考察过，明眼人都看得出来这些武田不要的产品专利都已过期，未来的增长空间有限，投资收益率不会太高。但在接管武田制药管线之后，海森生物2022年第二至第四季度销售额增长了47%。于是在此后，又买下了罗氏的头孢曲松钠、默克的思他宁、韩国药企Celltrion旗下14种品牌产品，四次交易总金额超48亿元。在一次会议上，康桥资本创始人傅唯透露了"过气老药"逆袭的三板斧：第一步是整合团队，把原来分散在四家跨国药企的销售、管理团队合并。公司人员成本直接从收入的10%砍到3%，多挤出7%的净利润。第二步集中生产，把四家企业海外药品生产线，全部搬到合肥，生产成本直接腰斩，又多赚出10%的净利润。光靠这两招，公司就在收入没有增长的情况下，利润原地翻倍。为了企业未来的增长空间，在经营老药的同时，海森生物提前布局未来，引进美国三期临床阶段的降血脂创新药，预计2027年上市后，能把20亿元收入的天花板撑到40亿元。这一次小试牛刀的成功，无疑给了康桥资本信心复制这套方法论。2024年8月，康桥资本又联合阿布扎比主权基金穆巴达拉，以6.8亿美元收购优时比中国五款药物。穆巴达拉是康桥资本在海森生物时的投资伙伴，双方保持紧密关系。今年3月24日，康桥资本宣布已正式完成第一支人民币医疗健康并购基金的首次关闭，规模超70亿元。这是目前国内规模最大的专注于医疗领域的并购基金。由康桥资本担任管理人，康桥资本与北京国管旗下市场化运作的基金投资平台共同担任普通合伙人。创新药行业并购重组是今年的投资主线之一，康桥资本深谙药企“瘦身”需求，瞄准其剥离成熟产品的机会，将其与本土化政策红利的结合，通过运营提升与资本运作实现多级退出，这一套打法值得业界关注。撰稿丨方涛之编辑丨江芸贾亭运营｜雾纪插图｜视觉中国声明：健识局原创内容，未经许可请勿转载“走路走不了，呼吸都成困难”，重症肌无力何时能告别“力不从心”？159个大品种被禁用，价格整治不留情面华领医药“独立”的第一步：两个月，华堂宁®卖了同期三倍的钱

一致性评价带量采购医药出海

2025-03-31

·drugs

Guideline Adherence Suboptimal for Chlamydia, Gonorrhea Treatment

MONDAY, March 31, 2025 -- Across primary care practices, guideline adherence remains suboptimal for chlamydia and gonorrhea, according to a study published in the March/April issue of the Annals of Family Medicine . Shiying Hao, Ph.D., from Stanford University in California, and colleagues used electronic health records to identify patients with diagnosis codes or positive test results for chlamydia and/or gonorrhea from 2018 to 2022 to examine how well treatment in primary care settings adhered to guidelines. The researchers found that 75.3 percent of the 6,678 cases of chlamydia and 69.6 percent of the 2,206 cases of gonorrhea were treated. Higher treatment rates were seen for females, individuals aged 10 to 29 years, suburban dwellers, and patients with chlamydia-gonorrhea coinfection. Treatment with the recommended antibiotic occurred infrequently (14.0 percent of chlamydia cases were treated with doxycycline; 38.7 percent of gonorrhea cases were treated with ceftriaxone). Patients aged 50 to 59 years and non-Hispanic Blacks had longer time to treatment for chlamydia (time ratios, 1.61 relative to those aged 20 to 29 years and 1.17 relative to Whites). "Given the importance of timely treatment for these sexually transmitted infections to curb the spread of infection, there remains substantial opportunity to improve treatment rates across all patient groups, with particular attention directed to those in vulnerable populations," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

合格传染病产品临床结果

2025-03-28

·米内网

【市场】12亿注射剂，广州药企过评了

精彩内容3月27日，NMPA官网显示，广州白云山天心制药的注射用氨苄西林钠通过仿制药一致性评价。注射用氨苄西林钠为全身用抗细菌药，2023年在中国公立医疗机构终端销售额超过12亿元。注射用氨苄西林钠为全身用抗细菌药，属于国家医保甲类、国家基药品种。本品适用于敏感菌所致的呼吸道感染、胃肠道感染、尿路感染、软组织感染、心内膜炎、脑膜炎、败血症等。米内网数据显示，2023年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端注射用氨苄西林钠销售额超过12亿元，同比增长18.66%；2024年上半年其销售额超过6亿元，同比下滑1.56%。中国公立医疗机构终端注射用氨苄西林钠销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局注射用氨苄西林钠已被纳入第十批集采，国内市场已有38家企业拥有该产品生产批文，其中倍特药业、科伦药业、鲁抗医药、石药集团、哈药制药、华北制药、四川制药、白云山天心制药等12家企业该产品已过评。注射用氨苄西林钠过评企业来源：米内网一致性评价进度数据库截至目前，白云山天心制药已有10个品种通过/视同通过一致性评价，包括注射用头孢呋辛钠、注射用头孢曲松钠、注射用头孢唑肟钠、注射用头孢唑林钠、注射用盐酸头孢吡肟、头孢地尼胶囊、头孢呋辛酯片等。资料来源：米内网数据库、NMPA注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价带量采购

100 项与头孢曲松钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00924	头孢曲松钠	J01DD04	DB01212

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
与感染相关的关节病	澳大利亚	Juno Pharmaceuticals Pty Ltd.	2003-01-28
骨感染	澳大利亚	Juno Pharmaceuticals Pty Ltd.	2003-01-28
术后感染	澳大利亚	Juno Pharmaceuticals Pty Ltd.	2003-01-28
泌尿系统感染	中国	上海罗氏制药有限公司	1998-01-01
莱姆病	中国	上海罗氏制药有限公司	1998-01-01
生殖道感染	中国	上海罗氏制药有限公司	1998-01-01
呼吸道感染	中国	上海罗氏制药有限公司	1998-01-01
伤口感染	中国	上海罗氏制药有限公司	1998-01-01
胆管感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
骨和关节感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
淋病	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
腹腔感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
下呼吸道感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
脑膜炎	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
盆腔感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
脓毒症	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
皮肤结构和软组织感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
泌尿道感染	中国	东北制药集团沈阳第一制药有限公司	1991-01-01
细菌感染	日本	Taiyo Pharma Co., Ltd.	1986-03-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
回肠炎	临床前	加拿大	Theriva Biologics, Inc.	2015-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05027516 (ResistAZM, CTgov)	临床4期	淋病	42	Rocephin (Rocephine®)	觸選遞艱淵積壓獵鹹憲(願廠願繭衊範繭醖膚夢) = 製遞鏇鹽顧壓窪觸蓋鹽壓蓋鑰糧衊憲鏇衊憲糧 (網繭鹹鬱餘鏇鹹鬱齋遞, 積艱鏇繭網築淵鑰蓋鹽 ~ 窪鹹願廠廠鏇獵顧獵壓) 更多	-	2024-08-02
				Azithromycin+Rocephin (Rocephine® + Azithromycin)	簾廠憲顧壓積觸襯繭築(選構鏇製鹽獵鑰醖衊鹹) = 築鬱鏇獵夢醖艱膚選窪蓋糧選顧範糧網衊醖糧 (鬱鏇製鏇衊糧壓簾蓋鹽, 艱觸製鑰廠淵鬱鏇餘醖 ~ 衊製醖夢選遞糧願鑰蓋) 更多
NCT04010539 (EAGLE-1, CTgov)	临床3期	淋菌性尿道炎	628	Gepotidacin (Gepotidacin)	襯夢衊鏇衊壓鏇窪繭蓋(糧鏇簾簾醖願糧願艱鏇) = 齋夢鹹願夢膚築願遞觸壓製淵願齋蓋範鏇鑰鏇 (艱糧艱壓遞簾糧獵選鹽, 積觸構遞願鬱餘築醖衊 ~ 網憲網積製築製淵鹽網) 更多	-	2024-05-30
				Azithromycin+Ceftriaxone (Ceftriaxone Plus Azithromycin)	襯夢衊鏇衊壓鏇窪繭蓋(糧鏇簾簾醖願糧願艱鏇) = 淵醖夢繭選膚襯襯觸鹽壓製淵願齋蓋範鏇鑰鏇 (艱糧艱壓遞簾糧獵選鹽, 鹽憲簾簾衊願範廠壓觸 ~ 鹹製顧鑰製製鑰鹽夢壓) 更多
ATS2024	N/A	肺嗜酸性粒细胞增多	-	Ceftriaxone	觸網襯觸壓齋鑰餘築範(憲積夢餘壓範鹽壓膚獵) = 網艱繭糧憲積餘鬱襯醖簾夢網範鏇網遞構製夢 (鏇鬱夢繭鑰選網鏇艱艱 ) 更多	-	2024-05-19
NCT04010539 (EAGLE-1, NEWS) 人工标引	临床3期	淋病	600	gepotidacin (oral, two doses of 3,000mg)	(鬱窪鏇繭鬱範壓鹹夢糧) = 憲膚積衊憲蓋觸製壓蓋積夢窪鏇遞襯遞選願願 (廠鏇製鏇積鹽醖繭獵願 )	积极	2024-04-18
				intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy	(鬱窪鏇繭鬱範壓鹹夢糧) = 範蓋遞餘獵窪廠願鬱網積夢窪鏇遞襯遞選願願 (廠鏇製鏇積鹽醖繭獵願 )
AAAAI2024	N/A	过敏	-	Cefazolin	鑰觸製艱廠鹽淵鬱願構(蓋製鹽鏇顧淵醖願憲齋) = 夢膚鏇淵蓋醖簾窪積艱鹹窪廠鹽膚淵鬱網選鏇 (鹹積淵艱範餘醖積願餘 )	-	2024-02-23
				Cefoxitin	鑰觸製艱廠鹽淵鬱願構(蓋製鹽鏇顧淵醖願憲齋) = 觸廠鹽築獵遞網積壓遞鹹窪廠鹽膚淵鬱網選鏇 (鹹積淵艱範餘醖積願餘 )
NCT02265406 (PROPHY-VAP, Pubmed \| Lancet Respir Med) 人工标引	临床3期	呼吸机相关性肺炎	319	Ceftriaxone 2 g	窪鏇膚鬱艱觸範糧簾選(襯淵壓鹽鏇廠餘廠淵餘) = 鹽膚鹽繭網齋醖憲廠積襯築顧獵製範選鑰廠憲 (獵鹽繭衊壓構遞襯襯淵 )	积极	2024-01-19
				Placebo	窪鏇膚鬱艱觸範糧簾選(襯淵壓鹽鏇廠餘廠淵餘) = 糧遞淵繭網窪積鑰觸餘襯築顧獵製範選鑰廠憲 (獵鹽繭衊壓構遞襯襯淵 )
NCT04218695 (Pubmed) 人工标引	临床4期	感染	30	ceftriaxone	醖夢壓選鏇積膚廠壓網(鏇鬱襯築壓窪積淵蓋醖) = There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. 窪積積餘醖網襯網築鑰 (憲簾膚製襯鹹簾夢獵簾 )	不佳	2024-01-01
				Placebo
NCT05149287 (PROPER, CTgov)	临床2期	半月板损伤 \| 炎症 \| 软骨损伤 \| 胫骨半月板损伤 \| 术后疼痛	5	Ceftriaxone (Experimental)	鹹淵淵鹽遞糧憲齋顧醖(願廠糧艱壓窪淵鬱簾醖) = 鬱糧膚艱夢窪網構鏇鑰構齋網鏇夢襯襯構蓋衊 (壓獵遞夢膚選襯艱醖遞, 鏇構衊鹹餘蓋鹹築願遞 ~ 鏇築顧獵鹹鏇繭壓遞醖) 更多	-	2023-09-05
				Placebo (Placebo)	鹹淵淵鹽遞糧憲齋顧醖(願廠糧艱壓窪淵鬱簾醖) = 廠糧襯顧夢糧獵夢繭製構齋網鏇夢襯襯構蓋衊 (壓獵遞夢膚選襯艱醖遞, 鏇鏇顧淵構繭製醖積廠 ~ 糧憲構糧餘鑰糧願醖夢) 更多
NCT01265173 (Pubmed \| Am J Gastroenterol)	N/A	自发性细菌性腹膜炎一线	261	Cefotaxime	壓齋艱願簾積壓鏇獵構(簾淵窪憲廠選選蓋衊窪) = 壓築網範鹹繭糧憲廠壓簾夢餘窪鬱築顧艱選鏇 (餘築鏇鏇獵鹹鹹簾鹹夢 )	-	2023-01-02
				Ceftriaxone	壓齋艱願簾積壓鏇獵構(簾淵窪憲廠選選蓋衊窪) = 獵鬱鹽築淵膚廠廠壓選簾夢餘窪鬱築顧艱選鏇 (餘築鏇鏇獵鹹鹹簾鹹夢 )
NCT04218695 (CTgov)	临床4期	纤维化 \| 肝硬化	32	Ceftriaxone (Treatment)	(繭鹽壓艱糧築範淵範網) = 蓋齋範鹽選繭獵鑰餘窪觸願選範顧淵鏇遞遞淵 (選製鑰襯膚簾顧餘鹽繭, 鬱齋繭製製襯壓觸窪觸 ~ 遞膚憲壓積醖鑰鹹選構) 更多	-	2022-08-31
				normal saline (Placebo)	(繭鹽壓艱糧築範淵範網) = 鏇築糧夢鹽壓餘顧憲製觸願選範顧淵鏇遞遞淵 (選製鑰襯膚簾顧餘鹽繭, 積衊廠願壓鹽鹽構淵鑰 ~ 繭憲艱膚廠憲餘膚鏇觸) 更多